Black Diamond Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026, in a virtual format. The meeting confirmed the election of Shannon Campbell and Kapil Dhingra as Class III directors, each to serve a three-year term. PricewaterhouseCoopers LLP was ratified as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders approved, on an advisory basis, the compensation of the company's named executive officers. A majority of stockholders also voted in favor of holding future advisory votes on executive compensation annually.